Policy | July 26, 2022
Funds for R&D in drug discovery and manufacturing :PIB
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
The Elecsys Amyloid Plasma Panel has the potential to ensure better identification of patients that require further confirmatory testing, supporting a more timely and accessible diagnosis.
The company now exceeds the sector benchmark for its overall ESG rating and for all three measures
PM congratulates citizens on crossing the 200 crore milestone of Covid vaccination drive
ABDM Hackathon Round 1 – Kickstarting Unified Health Interface (UHI) is being held from 14th to 17th July 2022 as a hybrid event
Groundbreaking collaborative research program will explore common characteristics of glaucoma, alzheimer's
Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru
The company was directed to submit a plan of compliance by July 15, 2022
Syngene's collaboration with Zoetis started in 2011
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Subscribe To Our Newsletter & Stay Updated
